الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 145 |  |  |
| | | from | 145 | | |
Abstract
In Egypt, BC is the second most common cancer in male population (12.6%) and becomes the third most common one in both sexes (7.9%) according to data Globocan 2020 of IARC. With an increased incidence of TCC and decrease in SCC from 73% to 25%in contrast to the findings in the earlier Egyptian series.
The lncRNAs are considered as a group of RNA which do not encode for proteins, and the lengths of these molecules are more than 200 nucleotides, they interact with DNA, RNA or proteins as molecular sponges, scaffolds and activators to play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to human diseases, especially in cancers.
The aim of this work was to evaluate the role of plasma lncRNAs UCA1 and MALAT1 in BC patients.
A total of 210 (123 males and 87 females) subjects were enrolled in this study. Subjects were divided as follows.
- group I: included 70 BC patients. Their age ranged from 43 to 62 years and were 59 males and 11 females.
- group II: included 70 Patients diagnosed with benign urinary tract disease as UTI or urethral stricture. Their age ranged from 40 to 56 years and were 51 males and 19 females.
- group III: included 70 of apparently healthy persons age and gender matched. Their age ranged from 39 to 63 years and were 53 males and 17 females.
All participants were subjected to detailed history, full clinical examination, pathological diagnosis, liver function tests, kidney function tests, complete blood count, urine analysis and assessment of expression of lnc RNAs UCA1 and MALAT1 by real time PCR technique.
The obtained results were as follow:
There were significant statistical differences between studied groups as regard to smoking and family history (P<0.001), while there was not significant statistical difference as regard to schistosomiasis. There were significant statistical differences between group I and group II as regard to hydronephrosis, gross hematuria and Irritative symptoms (P<0.05). Regarding laboratory investigations, there were significant statistical differences between the studied groups as regard to microscopic hematuria, creatinine, urea and hemoglobin (P<0.05), while there was no significant statistical difference as regard to ALT or AST. There was a significant statistical increase of UCA1 expression in BC patients when compared with the other groups (P<0.001). Regarding relation of UCA1 with demographic data and clinical findings, there were significant increase of UCA1 expression in relation with hydronephrosis (P=0.004), while there was no significant increase in relation with gender, smoking, schistosomiasis, gross hematuria, irrigative symptoms or microscopic hematuria in BC patients. Also, there was a significant increase of UCA1 expression in relation with stage, nodal status, metastasis and grade (P<0.05) while there was no significant elevation with histopathological type in BC group. The ROC curve of UCA1 for discrimination between BC group (GI) and non-cancer patients (GII+GIII) showed that the cutoff point was > 14.3 where the area under the curve was 0.969. The sensitivity was 87.14%, the specificity was 98.57%, the positive predictive value was 96.8% and the negative predictive value was 93.9%.